Author | Alana Hippensteele, Editor


Positive Results Announced From Phase 3 Adult Studies Evaluating 15-valent Pneumococcal Conjugate Vaccine

September 14, 2020

Two phase 3 studies showed an investigational 15-valent pneumococcal conjugate vaccine (V114, Merck) was well-tolerated among patients and met the primary immunogenicity objectives.

Department of Defense Awards Adaptive Phage Therapeutics $9.8 Million for Development of COVID-19 Vaccine

August 26, 2020

The Department of Defense awarded Adaptive Phage Therapeutics $9.8 million for the development of multiple high-priority, bacteriophage-based display vaccine candidates against COVID-19.

Update on Pharmacogenomic Testing and Use in Behavioral Health Treatment for Pediatric Patients

July 15, 2020

At the 2020 Virtual Conference on Pediatric Health Care, Kimberly Erlich presented an update on current understandings of pharmacogenomic testing and its use as a tool in the treatment of behavioral health issues in a pediatric population.

Diagnosing ADHD in Children and Teens Following a Failure in First-line Medications

July 07, 2020

The diagnosis and treatment of attention deficit hyperactivity disorder (ADHD) in children and teens can be a complex and unique challenge for providers.